UR Medicine Chooses DexCare to Power On-Demand Virtual Visits

New offering expands care access to serve more patients across New York through UR Medicine’s Get Care Now program; sees strongly positive responses from early users SEATTLE–(BUSINESS WIRE)–DexCare, Inc., the leading data-driven intelligence company focused on creating exceptional healthcare access experiences for everyone, today announced an agreement with UR Medicine, the clinical enterprise of the … [Read more…]

Axalbion to Present Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort MANCHESTER, England & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#TRPM8agonist–Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, announced that it will present positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 … [Read more…]

Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal

Novel optical imaging agent highlights cancerous tissue during initial lumpectomy to enable a more complete resection as part of the investigational Lumicell Direct Visualization System LUMISIGHT was previously granted Fast Track designation by the FDA Pan-oncological optical imaging agent also being studied for other solid tumors NEWTON, Mass.–(BUSINESS WIRE)–#BreakthroughDevice—Lumicell, Inc., a privately held company focused … [Read more…]

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors. Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the … [Read more…]

2023 International Forum on Consciousness to Explore Nature, Earth and Humanity: Evolution of Connection

Annual Forum dedicated to exploration of consciousness to be held May 18-19 in Madison, WI MADISON, Wis.–(BUSINESS WIRE)–#awakening–The 2023 International Forum on Consciousness will draw thought leaders and researchers to Madison, WI May 18-19 to explore relationships of human society to the planetary environment and to the larger dimension of time and space. Now in … [Read more…]

ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, … [Read more…]

Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia

Previously authorized for pediatric populations, critical care teams in Europe and Canada can now utilize Etiometry’s IVCO2 Index™ to determine the likelihood of inadequate carbon dioxide ventilation in adults BOSTON–(BUSINESS WIRE)–#CEmark—Etiometry, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 Index™ for adult populations, … [Read more…]

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

The proof-of-concept open-label study evaluated the safety and tolerability, function of regulatory T cells (Tregs), biomarkers, and preliminary efficacy (as measured by the ALSFRS-R scale) of COYA 302 over 48 weeks and was conducted in four ALS patients at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Jason Thonhoff. Study data showed no … [Read more…]

Mispro Biotech Services Celebrates 20th Anniversary with a Fresh Look: Company Unveils Brand Refresh to Mark Two Decades of Innovation and Growth

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#biosciences–Mispro Biotech Services, North America’s pioneering contract vivarium organization (CVO), is proud to announce its 20th anniversary and brand refresh to commemorate the occasion. Since its founding in 2003, Mispro has established itself as a trusted partner for biotech and biopharma companies seeking high-quality laboratory animal research facilities and services. As the company … [Read more…]

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

Results from the CLARITY Study Show the NEUROMARK® System Provides Safe and Effective Treatment for Patients with Chronic Rhinitis GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK® System … [Read more…]